Shots:

• The companies enter into precision medicine collaboration to discover and develop first-in-class therapies to treat patients with NSCLC. The companies will share the development cost while Evotec will be responsible for partnering of the programs and the platform
• The agreement will merge Evotec’s bioinformatics analysis platform “PanHunter’’ and its small molecule & Ab discovery platforms with the NSCLC cohort of Indivumed’s IndivuType multi-omics platform along with its advanced analytics and AI capabilities
• The agreement follows the previous agreement of the companies signed in Apr’2019 for colorectal cancer in which companies identified drug targets by Sept’2019 and will be used to develop therapies for colorectal cancer

Click here ­to­ read full press release/ article | Ref: Evotec | Image: Evotec